Cochrane · systematic review · CD011648
Pharmacological interventions for primary biliary cholangitis
Saffioti, F, Gurusamy, KS, Eusebi, LH, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
28
current version
GRADE rated
11
No studies
17
Included studies
NR
No studies 17 · 60.7%Ungraded 0 · 0%Very low 11 · 39.3%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Ursodeoxycholic acid (UDCA) versus no intervention for primary biliary cholangitis
Population: people with primary biliary cholangitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality at maximal Ursodeoxycholic acid (UDCA) vs no intervention | OR 0.99 [0.6, 1.64] | 6 studies · 734 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (proportion) Ursodeoxycholic acid (UDCA) vs no intervention | no estimate extracted | 3 studies · 380 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (number of events) Ursodeoxycholic acid (UDCA) vs no intervention | no estimate extracted | NR | No studies |
Health‐related quality of life Ursodeoxycholic acid (UDCA) vs no intervention | no estimate extracted | NR | No studies |
Azathioprine versus no intervention for primary biliary cholangitis
Population: people with primary biliary cholangitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality at maximal Azathioprine vs no intervention | OR 0.56 [0.32, 0.98] | 2 studies · 224 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (proportion) Azathioprine vs no intervention | no estimate extracted | NR | No studies |
Serious adverse events (number of events) Azathioprine vs no intervention | no estimate extracted | NR | No studies |
Health‐related quality of life Azathioprine vs no intervention | no estimate extracted | NR | No studies |
Colchicine versus no intervention for primary biliary cholangitis
Population: people with primary biliary cholangitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality at maximal Colchicine vs no intervention | OR 0.77 [0.32, 1.85] | 2 studies · 122 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (proportion) Colchicine vs no intervention | no estimate extracted | 1 study · 64 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (number of events) Colchicine vs no intervention | no estimate extracted | NR | No studies |
Health‐related quality of life Colchicine vs no intervention | no estimate extracted | NR | No studies |
Ciclosporin versus no intervention for primary biliary cholangitis
Population: people with primary biliary cholangitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality at maximal Ciclosporin vs no intervention | OR 0.88 [0.51, 1.5] | 3 studies · 390 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (proportion) Ciclosporin vs no intervention | no estimate extracted | NR | No studies |
Serious adverse events (number of events) Ciclosporin vs no intervention | no estimate extracted | NR | No studies |
Health‐related quality of life Ciclosporin vs no intervention | no estimate extracted | NR | No studies |
D‐Penicillamine versus no intervention for primary biliary cholangitis
Population: people with primary biliary cholangitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality at maximal D‐Penicillamine vs no intervention | OR 0.9 [0.57, 1.44] | 5 studies · 423 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (proportion) ( D‐Penicillamine vs no intervention | OR 28.77 [1.57, 526.67] | 1 study · 52 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (number of events) D‐Penicillamine vs no intervention | no estimate extracted | NR | No studies |
Health‐related quality of life D‐Penicillamine vs no intervention | no estimate extracted | NR | No studies |
Colchicine plus ursodeoxycholic acid (UDCA) versus UDCA for primary biliary cholangitis
Population: people with primary biliary cholangitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality at maximal Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA | OR 1.84 [0.38, 8.91] | 2 studies · 158 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (proportion) Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA | OR 3.08 [0.12, 78.14] | 1 study · 74 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (number of events) Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA | no estimate extracted | NR | No studies |
Health‐related quality of life Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA | no estimate extracted | NR | No studies |
Methotrexate plus ursodeoxycholic acid (UDCA) versus UDCA for primary biliary cholangitis
Population: people with primary biliary cholangitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality at maximal Methotrexate plus ursodeoxycholic acid (UDCA) vs UDCA | OR 1.17 [0.55, 2.51] | 2 studies · 290 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (proportion) Methotrexate plus ursodeoxycholic acid (UDCA) vs UDCA | no estimate extracted | NR | No studies |
Serious adverse events (number of events) Methotrexate plus ursodeoxycholic acid (UDCA) vs UDCA | no estimate extracted | NR | No studies |
Health‐related quality of life Methotrexate plus ursodeoxycholic acid (UDCA) vs UDCA | no estimate extracted | NR | No studies |